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a b s t r a c t
Carbohydrate fatty acid sulphate esters (CFASEs) formulated in a squalane-in-water emulsion are effec-
tive adjuvants for humoral responses to a wide range of antigens in various animal species but rise in
body temperature and local reactions albeit mild or minimal hampers application in humans. In rabbits,
body temperature increased 1 C one day after intramuscular (IM) injection, which returned to normal
during the next day. The effect increased with increasing dose of CFASE but not with the number of injec-
tions (up to 5). Antigen enhanced the rise in body temperature after booster immunization (P < 0.01) but
not after priming. Synthetic CFASEs are mixtures of derivatives containing no sulphate, one or multiple
sulphate groups and the monosulphate derivatives (CMS) were isolated, incorporated in a squalane in-
water emulsion and investigated. In contrast to CFASE, CMS adjuvant did not generate rise in body tem-
perature or local reactions in rabbits immunized with a purified, recombinant malaria chimeric antigen
R0.10C. In comparison to alum, CMS adjuvant revealed approximately 30-fold higher antibody titres after
the first and >100-fold after the second immunization. In ferrets immunized with 7.5 lg of inactivated
influenza virus A/H7N9, CMS adjuvant gave 100-fold increase in HAI antibody titres after the first and
25-fold after the second immunisation, which were 10–20-fold higher than with the MF59-like
AddaVax adjuvant. In both models, a single immunisation with CMS adjuvant revealed similar or higher
titres than two immunisations with either benchmark, without detectable systemic and local adverse
effects. Despite striking chemical similarities with monophospholipid A (MPL), CMS adjuvant did not acti-
vate human TLR4 expressed on HEK cells. We concluded that the synthetic CMS adjuvant is a promising
candidate for poor immunogens and single-shot vaccines and that rise in body temperature, local reac-
tions or activation of TLR4 is not a pre-requisite for high adjuvanticity.
 2017 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Novel adjuvants are needed for the new generation of well-
defined antigens to improve the level and duration of immunity
and to reduce the number of non-responders. Of particular interest
is their use in emergency vaccines thereby reducing the dose of
antigen and the number of injections. Avoiding the need for a boos-
ter reduces costs, time-to-immunity and complexity of vaccination
campaigns, which are critical factors in regions with poor infras-
tructure and in emergency situations. Furthermore, one instead
of multiple vaccinations results in lower overall risks of adverse
events associated with vaccination.
Synthetic carbohydrate fatty acid sulphate esters (CFASEs)-
based adjuvants are known for several years to effectively enhance
humoral responses to a wide range of antigens [1–8] in different
animal species. Multiple cycles of lead-finding and optimisation
focused on efficacy/toxicity (E/T)-ratio and structure-response-
relationship in large, non-rodent species, resulted in a series of
CFASE adjuvants. Incorporated into a squalane-in-water emulsion,
CFASEs exerted strong synergy [1–4] and outperformed oily adju-
vants with respect to efficacy, safety and quality [4,9–13], which
is unprecedented for an aqueous adjuvant formulation.
The first generation of CFASE adjuvants consisted of polysaccha-
ride derivatives and is exploited in single-shot vaccines for veteri-
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nary purposes [3] and investigated in a cancer vaccine [14,15]. The
second generation based on a disaccharide known as ‘CoVaccine
HTTM [4–6] reached phase IIa clinical trial with two therapeutic,
peptide-protein vaccines [16,17]. Drawbacks of these CFASEs are
rise in body temperature one day after injection and local reactions
at the site of injection albeit mostly mild or minimal. To annihilate
these adverse effects while retaining adjuvanticity, we examined
several factors influencing E/T-ratio including dose of adjuvant
and antigen, number of injections and chemical structure of the
active molecule. Results on a third generation of carbohydrate
derivatives are reported here.
2. Materials and methods
2.1. Antigens
Three different antigens were used to assess in vivo perfor-
mance of the adjuvants. A peptide-protein conjugate
(gonadotropin-releasing hormone peptide coupled to keyhole
limpet haemocyanin; ‘GnRH-KLH’) prepared for nonclinical GLP
toxicity studies as described by Turkstra et al. [13] was used at
400 and 800 lg of protein per dose. A chimeric recombinant
malaria antigen R0.10C composed of a fragment of Plasmodium
falciparum glutamate rich protein fused with a correctly folded
fragment of Pfs48/45, produced in Lactococcus lactis and
immune-purified ([18]; Radboud UMCN, Nijmegen, The Nether-
lands) was used at 10 lg protein per dose. Whole virion A/H5N1
and A/H7N9 grown on cell culture, inactivated and purified, were
kindly provided by National Health Research Institute of Taiwan
and Medigen Vaccine Biologicals Corp. (Taipei, Taiwan) and used
at 7.5 lg HA per dose.
2.2. Adjuvants
CFASEwas prepared as described byBlomandHilgers [4]. Briefly,
maltose dissolved in pyridine plus N,N-dimethylformamide was
contacted with one equivalent of SO3.pyridine and 8 equivalents
of decanoylchloride. Monosulphate derivatives (CMS) and polysul-
phate derivatives (CPS)were isolated from the CFASE by preparative
liquid chromatography on silica with 12 v/v% triethylamine and 12
v/v% 2-isopropanol in n-heptane (all from Sigma-Aldrich, St. Louis,
MO) as eluent. Fractions containing either CMSor CPS as determined
by thin layer chromatographywere pooled anddried andpuritywas
determined by LC-MS.
Adjuvant formulations were prepared by passing mixtures of
40 g of CFASE or CMS or CPS, 80 g of squalane (Bayer, Germany),
40 g of Polysorbate 80 (Montannox 80 PPI; Seppic, Paris, France)
and 840 g phosphate buffered saline (PBS; Fisher Scientific) three
times through a high-pressure emulsifier (Microfluidizer Y110,
Microfluidics, Newton, USA). The submicron emulsions obtained
were passed through a 0.2 lm filter (PES Supor EKV, Pall Life
Sciences, Portsmouth, UK), stored in sterile containers at 4 C and
tested as described below.
Alhydrogel (Brenntag Biosector, Frederikssund, Denmark) and
the MF59-like adjuvant AddaVax (InvivoGen, Toulouse, France)
were used as benchmarks.
Vaccines were prepared by mixing antigen, adjuvant and PBS at
appropriate volume ratio one day before administration. Prefilled
1-mL syringes with 0.5 mL (plus 0.1–0.2 mL excess) of either vac-
cine, equipped with 25G needles, labelled with animal ID, study
ID and date were supplied to the animal facility.
The dose of adjuvant was 22 mg of CFASE or 8 mg of CMS or
8 mg of CPS (22 mg CFASE contains approximately 8 mg CMS and
8 mg of CPS), 0.2 w/v% Alhydrogel or 50 v/v% of AddaVax.
2.3. Animals
SPF Female rabbits (New Zealand White, Harlan Laboratories,
UK), 3–6 months of age were housed individually with supply of
tap water ad libitum and 100 g food per animal per day.
Male ferrets (undisclosed provider in Denmark), 6–12 months
of age and negative for relevant (circulating and vaccine) influenza
strains (A/H7N9, A/H1N1, A/H3N2 and B) and Aleutian Disease
virus, were housed in standard group cages with ad libitum supply
of tap water and food (Hope Farms, Ferret super).
The animals were randomly assigned to treatment groups using
a generalized randomized block design on the base of body weight.
Animals were checked daily for overt signs of disease and
treatment-related adverse events.
2.4. Ethical statement
The use of animals was performed in accordance with the reg-
ulations set forth by the relevant national and/or local Ethical Com-
mittee for Animal Experimentation and in accordance with
European Community Directive 86/609. All the techniques and
procedures were refined to provide for minimal discomfort and
stress to the animals.
2.5. Immunization and blood collection
Test items in 0.5 mL were injected IM two times alternating in
the left and right thigh muscle at 3-week interval, unless stated
otherwise. At different time intervals before and after each immu-
nization blood samples of 1–5 mL were collected and rectal body
temperature was measured.
2.6. Antibody titres to malaria in rabbits
Antibody titres in serum samples were measured by Radboud
UMCN (Nijmegen, the Netherlands) by ELISAs with purified
R0.10C or gametocyte extract as coating antigens. Microtiter plates
(Sterilin ELISA plates, Netherlands) were coated overnight,
blocked with 5% milk in PBS, incubated with serial dilutions of
serum samples in PBS-0.05% Tween 20 (PBST) for 4 h at room tem-
perature, incubated with anti-rabbit IgG-HRP (H + L) (DAKO, Den-
mark) and developed with tetramethyl benzidine (TMB)
substrate solution for 20 min at room temperature. The colour
reaction was stopped with 0.2 N H2SO4 and the optical density
was read at 450 nm in a Microplate Reader (Labtec BV, Germany).
After each incubation step plates were washed extensively with
PBST – 0.5 M NaCl. A positive and negative control serum were
included in each test to confirm validity of the test. The antibody
concentration was expressed as the EC50-value calculated by using
GraphPad Prism (GraphPad Software, USA).
2.7. Antibody titres to H7N9 in ferrets
Antibody responses to H7N9 in ferrets were determined by Viro-
clinics Biosciences BV (Rotterdam, the Netherlands) as described
elsewhere [19]. Briefly, serum samples were pre-treated with cho-
lera filtrate resulting in a pre-dilution of 1:6 and serially two-fold
dilutions were tested in the HAI test using 2:6 reassortant (A/
Anhui/1/2013 H7N9 and A/PR/8/34) as described elsewhere [20].
2.8. Safety assessment in rabbits
Rectal body temperature of rabbits was measured 6 h before
and 3 or 6, 24, 48 and 96 h after each immunization. Local reac-
tions were determined by palpation and visual inspection during
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the life phase and by necropsy 7 days after the second immuniza-
tion (i.e. 28 days after the first immunization) as described else-
where [21]. The local reaction score at necropsy takes into
account the size and nature of the reaction as well as the time
interval between treatment and necropsy.
2.9. In vitro activation of human TLR4 expressed on HEK cells
CMS adjuvant was tested for its potential to activate human
TLR4 as described elsewhere [22,23]. Briefly, human endothelial
kidney (HEK293) cells transfected with TLR4-encoding construct
(InvivoGen, San Diego CA) and with reporter vector expressing
luciferase under the control of an NF-jB–responsive promoter
(InvivoGen) were plated in flat-bottom 96-wells plates at 1  105
cells/well. After incubation for 16 h at 37 C with test substance
in triplicate, cells were lysed in Steady Glo luciferase buffer (Pro-
mega Benelux, Leiden, The Netherlands) and bioluminescence
was measured using a Packard 9600 Topcount Microplate Scintilla-
tion & Luminescence Counter (Packard Instrument, Meriden, CT).
As positive control for NF-jB–mediated activation 25 ng/ml TNF-
a (PeproTech, London, U.K.) was used. As positive control for
TLR4 activation, 1 and 0.01 lg/mL of LPS (Sigma-Aldrich, St. Louis,
MO) was included. Mean values, SDs and variances were calculated
for each compound tested in triplicate.
2.10. Data processing and statistical analysis
The animal studies were conducted as blind, benchmark-
controlled, comparative studies and treatments of individual ani-
mals were disclosed only after collection and quality approval of
the data. For each group the geometric mean antibody titre
(GMT) of the 2Log-values of individual results, standard deviation
(SD), antilog-value (2 power GMT) and factor of increase were cal-
culated. Two-tailed Students’ t test at P-value  0.05 was selected
to establish statistical difference between groups.
3. Results
3.1. Effect of CFASE on body temperature in rabbits
In a repeated-dose study in rabbits, groups of 6 animals were
injected IM five times at 2-week intervals with 0, 20 or 40 mg of
CFASE adjuvant (‘CoVaccine HT’) plus 0, 400 or 800 lg of GnRH-
KLH as model antigen. After each injection, body temperature
was monitored (Fig. 2 and Table 1).
Three h post-treatment, none of the groups exhibited signifi-
cantly increased body temperature. Twenty-four h post-
treatment, animals injected with CFASE adjuvant with or without
antigen demonstrated an overall increase in body temperature of
0.9 C (P < 0.01), which disappeared during the next day. Forty
mg of CFASE gave 0.1 C higher body temperatures than 20 mg
(P < 0.01). CFASE adjuvant plus antigen induced on average 0.4 C
higher body temperature than CFASE adjuvant alone after the sec-
ond up to the fifth (P < 0.01) but not after the first injection
(P > 0.14). Rises in body temperature after the 5 consecutive treat-
ments remained constant.
3.2. Fractionation of CFASE and in vivo pilot study
CFASE of maltose was fractionated into derivatives with no sul-
phate, one sulphate per disaccharide (maltose fatty acid monosul-
phate esters; ‘CMS’) or two or more sulphates per disaccharide
(maltose fatty acid polysulphate esters; ‘CPS’). CMS and CPS were
96% pure as measured by LC-MS. In a pilot study with inactivated
H5N1 in rabbits CFASE, CMS and CPS formulated in squalane-in-
water emulsions gave comparable increases in HAI antibody titres.
H5N1 alone already gave rise in body temperature of 0.5–1.0 C
one day post-vaccination, which was not further increased by
either adjuvant (data not shown). One week after the second
immunization, local reaction score (i.e. the product of the volume
of abnormal muscular tissue multiplied by an arbitrary value of 1
for mild reactions such as discoloration, loss of structure and
oedema, 3 for moderate reactions such granuloma, mild inflamma-
tion and connective tissue, or 9 for severe reactions such as necro-
sis and abscess, see reference 21) with CPS adjuvant was >100-fold
higher than with CFASE adjuvant, CMS adjuvant or alum (data not
shown). In vitro CPS adjuvant but not CMS adjuvant exerted strong
haemolytic activity (data not shown) and therefore, we decided to
continue with CMS.
3.3. Adjuvant activity of CFASE, CMS and alum to a recombinant
malaria chimeric antigen in rabbits
A safety and immunogenicity study was conducted with a
recombinant, chimeric malaria recombinant protein. Effects of
CFASE adjuvant (CoVaccine HTTM), CMS adjuvant and alum on the
response to R0.10C and gametocyte extract were compared. After
the first immunization with no adjuvant or alum, no significant
or low ELISA antibody titres to R0.10C and gametocyte extract
were observed. CFASE and CMS adjuvant gave 31 and 20 fold
increases in antibody titres to R0.10C (Fig. 3a) and 2 and 5 fold
to gametocyte extract (Fig. 3b), respectively. After the second
immunization, responses increased significantly in all groups.
CFASE and CMS adjuvant generated >100-fold higher antibody
titres to both R0.10C and gametocyte extract as compared to anti-
gen alone and 50-fold higher as compared to alum. Responses with
CMS and CFASE adjuvant were similar and were significantly
higher than with alum (P < 0.001) or without adjuvant
(P < 0.0001). No significant increase in body temperature was
noted with CMS adjuvant (P > 0. 50) or alum (P > 0.14) after the
either immunization (Fig. 3c). CFASE adjuvant gave increases of
about 0.5 C after both the first and second immunization, which
were significantly higher than without adjuvant (P < 0.003 and
P < 0.004, respectively) or with CMS adjuvant (P < 0.034 and
P < 0.006, respectively).
3.4. Effects of CMS and AddaVax to inactivated whole-virion H7N9 in
ferrets
In addition to a subunit, CMS adjuvant was tested in combina-
tion with inactivated whole virus. Groups of 6 ferrets were injected
Fig. 1. Chemical structure of CMS molecule maltose 40-monosulphate
1,2,3,6,20 ,30 ,60-heptadecanoic acid ester.
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IM at Day 0 and 21 with 7.5 lg of inactivated, whole-virion influ-
enza virus strain A/H7N9 with or without adjuvant. At the start
of the study, none of the animals had detectable antibodies to
H7N9 in serum pre-diluted 5-fold. Three weeks after the first
immunization animals developed substantial levels of anti-H7N9
antibodies in serum (Fig. 4). Immunization without adjuvant
resulted in a GMT of 6 (mean 2log-value of 2.7 ± 0.8). AddaVax gave
5-fold (P < 0.004) and CMS 100-fold (P < 0.001) higher HAI anti-
body titres.
The second immunization increased the antibody titres in all
but 2 animals by a factor of at least 2. One animal in the group
without adjuvant and one in the AddaVax adjuvant group did not
demonstrate increased HAI titres. Three weeks after the second
immunization, GMT without adjuvant was 96 (mean 2log of
6.6 ± 2.3) with AddaVax 335 (mean 2log-value of 8.4 ± 1.1) and
with CMS adjuvant 2429 (mean 2log-value of 11.3 ± 0.3). CMS adju-
vant but not AddaVax generated significantly higher titres than
antigen alone (P < 0.0001 and P = 0.116, respectively). Responses
with CMS adjuvant were significantly higher than with AddaVax
(P < 0.001). In comparison to antibody levels prior to the second
immunization, boosts with no adjuvant, AddaVax or CMS adjuvant
resulted in 15, 11, or 4-fold increases in GMT, respectively.
To assess the persistence of circulating antibodies, anti-H7N9
HAI antibody titres were measured again 21 weeks after the first
immunization (Day 147). GMTs without adjuvant, with AddaVax
or CMS adjuvant were 23, 108 and 532, respectively. The response
to CMS adjuvant was significantly higher than to AddaVax
(P < 0.001) and the latter was significantly higher than to antigen
alone (P < 0.01). The calculated half-life of the HAI antibodies in
the period from day 42 to day 147 varied between 6 and 8 weeks.
Interestingly and observed also with the malaria subunit in rab-
bits, a single immunization with CMS adjuvant gave similar or
higher titres than two immunizations with the benchmark or with-
out adjuvant.
The study was not designed to determine systemic and local
adverse events other than general performance and health condi-
tions. No adverse effects were observed with either vaccine.
3.5. In vitro activation of human TLRs expressed on HEK cells
CMS was tested for its potential to activate human TLR4
expressed on HEK cells in vitro. TLR4 was not activated by CMS
adjuvant at concentrations of 100 or 1000 lg CMS per mL while
LPS at concentrations of 1.0 or 0.01 lg/mL caused 400–600-fold
increase in bioluminescence of the TLR4-transfected HEK cells
(Fig. 5). Lack of activation by CMS adjuvant was not the result of
cytotoxic effects as viability of the cells was not affected and cells
retained the ability to respond to LPS (J. Bajramovic, personal
communication).
4. Discussion
Despite several novel vaccine adjuvants (MF59, AS03, AS04,
AF01) and products in advanced stage of development (GLA-SE,
CAF01, IC31), there is still a need for more effective adjuvants for
a variety of applications. The successful development of a new gen-
eration of vaccines of well-defined antigens depends on more
effective adjuvants that are sufficiently safe for a particular use.
In addition, better adjuvants open possibilities for lower doses of
Fig. 2. Rectal temperature in rabbits after five injections at 2-week intervals with combinations of 0, 20 or 40 mg CFASE adjuvant plus 0, 400 or 800 lg of GnRH-KLH. Each
point represents the mean of a group of 6 animals. The arrows indicate the moment of IM injection. Group 1: 0 mg CFASE adjuvant + 0 lg GnRH-KLH (open squares); Group 2:
20 mg CFASE adjuvant + 0 lg GnRH-KLH (grey triangle); Group 3: 40 mg CFASE adjuvant + 0 lg GnRH-KLH (grey square); Group 4: 20 mg CFASE adjuvant + 400 lg GnRH-KLH
(black triangle); Group 5: 20 mg CFASE adjuvant + 800 lg GnRH-KLH (black square); Group 6: 40 mg CFASE adjuvant + 800 lg GnRH-KLH (black circle).
Table 1
Summary of the effects of different combinations of CFASE adjuvant and GnRH-KLH antigen on body temperature 24 h post injection in rabbits represented in Fig. 2.
Mean body temperature (C) ± SD 24 h post immunization 1–5 (group number is indicated between
parentheses)
Dose of GnRH-KLH antigen
0 lg 400 lg 800 lg Total
Dose of CFASE 0 mg 39.34 ± 0.15 (1) 39.34 ± 0.15
20 mg 39.92 ± 0.19 (2) 40.40 ± 0.10 (4) 40.16 ± 0.29
40 mg 40.12 ± 0.13 (3) 40.26 ± 0.05 (5) 40.42 ± 0.11 (6) 40.27 ± 0.16
Total 39.79 ± 0.37 40.33 ± 0.11 40.42 ± 0.11
Groups of 6 female rabbits were injected intramuscularly five times 2 weeks apart with 0, 20 or 40 mg CFASE adjuvant plus 0, 400 or 800 lg GnRH-KLH antigen. Body
temperature (C) was measured 24 h after each of the 5 injections and arithmetic mean values ± SDs of in total 30 observations per group are represented.
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antigen and fewer injections. Therefore, we investigated a novel
series of adjuvants based on synthetic carbohydrate esters. The
novel concept is the outcome of the stepwise optimization of E/
T-ratio of synthetic carbohydrate derivatives through analysis of
structure-activity relationship in larger, non-rodent species such
as pigs or rabbits. Efficacy was determined by immune responses
Fig. 3. Effect of immunization of rabbits with recombinant malaria chimeric antigen R0.10C alone (‘PBS) or with alum, CFASE adjuvant or CMS adjuvant on (a) the ELISA
antibody response to R0.10C, (b) the ELISA antibody response to Plasmodium falciparum gametocyte extract 21 days after the first (PV-1) and second vaccination (PV-2) and (c)
the body temperature one day after each immunization. Results are expressed as 95% confidence interval (‘95% CI’).
Fig. 4. GMT HAI antibody responses in ferrets at various time intervals after
immunization with 7.5 lg HA of inactivated, whole-virion influenza virus A/H7N9
with no adjuvant (diamonds), MF59-like AddaVax (squares) or CMS adjuvant
(circles).
Fig. 5. CMS adjuvant does not activate of TLR4 on HEK cells. Each test item was
analysed in triplicate and means are expressed as log values of the bioluminescence
measured. Variance (not indicated) was between 50 and 100% for CMS adjuvant and
less than 10% for the positive controls.
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after one or two immunizations with a purified, recombinant pro-
tein and toxicity was assessed by necropsy of local reactions after
two IM injections [19]. Advantages of larger non-rodent species
compared to small rodents, include that local reactions can be
quantified precisely and in an objective manner, projected human
doses of vaccine can be administered, and extrapolation to perfor-
mance in humans is thought to be more adequate.
CFASE adjuvants such as CoVaccine HTTM have been proven to be
highly effective to many types of antigens. Other research groups
reported that these adjuvants revealed similar or even higher
immune responses than oily adjuvants such as Freund’s Adjuvants
and ISA51 in nonhuman primates, pigs, rabbits and sheep [4,7–
10,13]. A recent paper reported that not only the quantity but also
the quality of the antibodies induced by CFASE adjuvant was
improved as compared to those elicited by Freund’s Complete or
Incomplete Adjuvant as demonstrated by stronger affinity and
enhanced functional potency [10]. This is unprecedented for an
aqueous product. Although CoVaccine HTTM-adjuvanted vaccines
passed formal preclinical toxicity assessment, rise in body temper-
ature one day after injection hampered further clinical develop-
ment. Therefore, we aimed at a novel generation of CFASE-based
adjuvants lacking this adverse effect while retaining high efficacy.
One approach was the separation of CFASE into fractions with
no sulphate or one (CMS), two or more sulphate (CPS) groups per
carbohydrate backbone and determination of E/T-ratio thereof.
CMS (Fig. 1) consists of monosulphate isomers and its purity
already offered important advantages in the characterization and
quality control of the product. In a feasibility study in rabbits,
CPS but not CMS adjuvant elicited significant local reactions.
Strong in vitro haemolytic activity of CPS but not CMS adjuvant
confirmed high surface-activity of derivatives with multiple sul-
phate and multiple fatty acid esters.
The CMS adjuvant comprises of a submicron emulsion of
squalane-in-water, stabilized by Polysorbate 80 and is comparable
with known products such as MF59, SE, and CoVaccine HTTM. Pas-
sage through 0.2 lm filter resulted in a sterile, ready-for-use for-
mulation of 4 well-defined chemicals. Based on 2-year stability
of lab batches of CMS adjuvant and >10-year stability of its prede-
cessors, we anticipate long-lasting chemical stability of ingredients
and physical stability of the formulation. The manufacturing pro-
cess is similar to the procedures established earlier for the prede-
cessors except that a purification step by liquid chromatography
is included.
For lead finding and optimization considering local reactions,
the pig was very useful. To examine effects of body temperature,
however, we decided to employ the rabbit as it is the standard spe-
cies for pyrogenicity testing of medicinal products. A repeated-
dose study revealed that CFASE with or without antigen induced
a significant but transient, dose-dependent increase in body tem-
perature of about 1 C one day after IM injection (Fig. 2). The spikes
remained constant for five consecutive treatments indicating that
no tolerance or increased sensitivity occurred. The addition of a
high-molecular peptide-protein conjugate as model antigen did
not increase the body temperature after the first injection. After
booster immunization, there was a slight increase in body temper-
ature, which was statistically significant when results with differ-
ent vaccines were taken together. Formation of antigen-antibody
complexes and/or activation of immunological memory may be
responsible for this additional effect.
Further analysis of immunogenicity and safety was conducted
with a small, well-defined subunit and inactivated whole virus at
much lower doses. The immuno-affinity purified, malaria chimeric
glycoprotein R0.10C with molecular weight of 90 kD produced in L.
lactis at a dose of 10 lg [24] was selected as it is a poor immuno-
gen. Two or three injections with adjuvant are needed for detect-
able immune responses in small rodents [22]. In the rabbit study
reported here, CFASE and CMS elicited similarly high antibody
responses after one and two injections and CFASE but not CMS eli-
cited fever in at least some animals (Fig. 3).
In a qualified model for influenza vaccines in ferrets, we exam-
ined the effects of CMS on the immune response to inactivated,
whole-virion A/H7N9 influenza virus. CMS gave 100-fold higher
HAI antibody titres after the first and 25-fold after the second
immunization, which were 20- and 8-fold higher than with Adda-
Vax (Fig. 4). Body temperature or local reactions were not analysed
in this study but daily monitoring of the animals for general beha-
viour and frequent palpation of the injection site did not exhibit
any adverse effects. A/H7N9 was used at 7.5 lg HA per injection
and as we demonstrated previously that 4 lg HA of H5N1 plus
CFASE elicited high responses in ferrets and macaques [6,7], the
antigen dose could be lowered further.
Remarkably, a single immunization with CMS adjuvant gener-
ated comparable or higher antibody titres than two immunizations
either with benchmark or without adjuvant. This is in accordance
with immunogenicity data on CFASE adjuvant but unique relative
to existing adjuvants. A recent comparative study revealed that
none of on existing adjuvants administered once reached the
anti-flu HAI antibody titre obtained by two immunizations without
adjuvant [25]. This interesting capacity of CMS adjuvant opens
possibilities of single-shot vaccines, which may result in decreased
costs of vaccination campaigns (goods, logistics and staffing),
reduced time-to-immunity, improved adherence and reduced
overall risks of vaccination.
The mechanisms underlying CMS adjuvant action is not yet
understood. CFASE adjuvant has been shown to induce fever
in vivo and to promote the maturation of human dendritic cells
in vitro, which could be blocked by anti-TLR4 antibodies [26]. As
CMS adjuvant did not cause fever or activate human TLR4
expressed on HEK cells (Fig. 5), we hypothesized that other compo-
nents of CFASE are responsible for these actions. These could be
derivatives with two or more sulphate groups present in CFASE
and CPS therefrom. Indeed, CPS but not CMS adjuvant elicited
strong local reactions at the site of injection and this could be
linked to fever and TLR4 activation. In this respect, there might
be some analogy with Lipid A and monophospholipid A where
removal of one phosphate group led to a distinct, more favourable
activity profile. But the striking difference between monophospho-
lipid A and CMS is their ability to activate TLR4 and further inves-
tigations are needed to solve this discrepancy. Furthermore,
detailed in vivo and in vitro analysis will contribute to our insights
in structure-response relationships of carbohydrate derivatives
with one or two sulphate groups instead of one or two phosphate
groups.
We concluded that CFASEs consist of different carbohydrate
derivatives with different profiles, that CMS is not responsible for
increased body temperature, local reactions and TLR4 activation
and that these (side-)effects are no pre-requisites for high adjuvant
activity. CMS adjuvant is a promising candidate for poor immuno-
gens and single-shot vaccines and further research is needed to
confirm its potentials and to elucidate the immunological mecha-
nisms involved.
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